Research programme: chimeric antigen receptor T-cell therapies - Generate Biomedicines/Roswell Park
Latest Information Update: 08 Dec 2023
At a glance
- Originator Generate Biomedicines; Roswell Park Cancer Institute
- Developer Generate Biomedicines
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Solid tumours